ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,664,750 | +95.5% | 215,000 | +152.9% | 3.04% | +155.3% |
| Q2 2023 | $3,921,050 | +1619.8% | 85,000 | +4150.0% | 1.19% | +2487.0% |
| Q1 2021 | $228,000 | -45.1% | 2,000 | -33.3% | 0.05% | -60.7% |
| Q4 2020 | $415,000 | -32.6% | 3,000 | -60.0% | 0.12% | -46.6% |
| Q3 2020 | $616,000 | -39.4% | 7,500 | -42.3% | 0.22% | -44.8% |
| Q2 2020 | $1,017,000 | -41.9% | 13,000 | -67.0% | 0.40% | -90.4% |
| Q1 2020 | $1,749,000 | +6.4% | 39,362 | +2.2% | 4.12% | +232.4% |
| Q4 2019 | $1,644,000 | +60.1% | 38,500 | +60.4% | 1.24% | +24.0% |
| Q3 2019 | $1,027,000 | – | 24,000 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |